The U.S. Food and Drug Administration (FDA) has approved a new pill for cancer treatment, known as Rasonque, developed by Revolution Medicines based in California. This medication is specifically designed to treat the most common kind of pancreatic cancer by targeting various forms of the RAS protein responsible for tumor growth. It is taken once a day.
In a statement, the FDA described Rasonque as “a new treatment option for patients with advanced pancreatic cancer,” emphasizing that the approval came more than six months earlier than expected. Acting FDA Commissioner Kyle Diamantas praised the approval, calling it a significant advancement for patients battling a particularly challenging type of cancer. He expressed pride in the FDA scientists whose dedication contributed to this important milestone.
Rasonque is intended for adults suffering from metastatic pancreatic cancer who have either not responded to at least one prior treatment or are not eligible for certain combination therapies. Pancreatic adenocarcinoma is one of the deadliest cancers and accounts for about 95% of the estimated 67,000 cases diagnosed each year in the United States, according to the National Cancer Institute. Although it represents only 3.2% of total cancer cases, it leads to a disproportionately high number of deaths due to late-stage diagnosis and rapid progression.
The approval of Rasonque followed a clinical trial involving 500 patients with pre-treated metastatic pancreatic cancer. The results indicated that patients taking Rasonque lived a median of 13.2 months, nearly doubling the survival rate of just 6.7 months seen in those receiving standard chemotherapy.
Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence, stated that the drug’s results marked a significant breakthrough in an area with high medical needs. To expedite this medication’s journey to the market, the FDA granted it priority review, orphan drug status, and breakthrough therapy designation.
In May, prior to the official approval, the FDA provided a “safe to proceed” letter, allowing patients to access the drug through an expanded access protocol.
While Rasonque offers new hope, it is essential for patients to be aware of the potential side effects. The most common adverse reactions reported include rashes, diarrhea, mouth sores, nausea, fatigue, vomiting, abdominal pain, fluid retention, reduced appetite, and bleeding.
According to Dr. Anna Berkenblit, chief scientific and medical officer of the Pancreatic Cancer Action Network, this approval marks a vital step forward in the fight against pancreatic cancer. She believes that this new treatment will not only improve patient outcomes but also enhance the quality of life for many individuals battling this challenging disease, providing them with hope for future advancements as research continues.
